Study Finds Racial, Gender Disparities in SGLT2 Inhibitor Use

by Jeff Minerd: For Complete Post, Click Here…

Drugs prescribed less often to Black, Asian, female, and lower-income type 2 diabetes patients.

Women, Black and Asian people, and those with lower incomes were less likely to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for their type 2 diabetes, according to a large retrospective study of claims data.

Furthermore, in more than 900,000 U.S. adults with type 2 diabetes, use of SGLT2 inhibitors increased from 3.8% in 2015 to 11.9% in 2019, but remained relatively low, reported researchers led by Lauren Eberly, MD, of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.

Use of this drug class in 2019 was notably lower than average among patients with heart failure with reduced ejection fraction (HFrEF; 7.6%), atherosclerotic cardiovascular disease (ASCVD; 9.8%), and chronic kidney disease (CKD; 7.5%), they noted in JAMA Network Open.

In multivariable analyses, Black patients were significantly less likely to receive an SGLT2 inhibitor (OR 0.83, 95% CI 0.81-0.85), as were Asian patients (OR 0.94, 95% CI 0.90-0.98), and women (OR 0.84, 95% CI 0.82-0.85).

Patients with a median household income of $100,000 or more, however, were more likely to receive an SGLT2 inhibitor (OR 1.08, 95% CI 1.05-1.10), as were those with incomes of $50,000 or more (OR 1.05, 95% CI 1.03-1.07) compared with those with a median household income less than $50,000.

“To our knowledge, this is the first study to investigate whether there is inequitable access to SGLT2 inhibitor treatment among commercially insured patients with type 2 diabetes in the United States,” Eberly’s group wrote.

Leave a Reply